New CAR T-Cell Therapy Promising for Multiple Myeloma
An experimental chimeric antigen receptor (CAR) T-cell therapy may be effective in treating multiple myeloma without the risk for severe cytokine release syndrome (CRS) associated with other CAR T-cell therapies, according to investigators.

The study, presented at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (abstract 14), examined the efficacy and safety of bb2121 (bluebird bio), a drug that redirects T cells to multiple myeloma by targeting B-cell maturation antigen (BCMA). BCMA is a member of the tumor necrosis factor family that is expressed almost solely by malignant myeloma cells, plasma cells and some mature B cells, the authors said....